芳香化酶抑制剂治疗晚期乳腺癌患者对其骨关节疼痛及生活质量的影响  

Effects of Aromatase Inhibitor Treatment on Bone Joint Pain and Quality of Life in Patients with Advanced Breast Cancer

作　　者：曹熹 CAO Xi(Department of General Surgery,Fujian Provincial Government Hospital,Fuzhou 350003,China)

机构地区：[1]福建省级机关医院普通外科,福建福州350003

出　　处：《中国医药指南》2023年第23期100-102,共3页Guide of China Medicine

摘　　要：目的 研究对晚期乳腺癌患者应用芳香化酶抑制剂治疗对其癌性疼痛及生活质量的影响。方法 于我院接受不同药物治疗的晚期乳腺癌患者中随机抽取30例,作为对照组(30例,依西美坦)和观察组(30例,来曲唑),对比两组的治疗效果。结果 观察组ORR(50.00%)和对照组(46.67%)对比差异无统计学意义(P> 0.05)。观察组不良反应发生率低于对照组(P <0.05)。两组关节疼痛差异无统计学意义(P> 0.05)。两组治疗4周后E2水平差异无统计学意义(P> 0.05);观察组治疗8周E2显著高于对照组(P <0.05)。观察组VAS评分显著低于于对照组(P <0.05);观察组患者SF-36评分显著高于对照组(P <0.05)。结论 来曲唑和依西美坦是治疗晚期乳腺癌常见的疗效相当,来曲唑不容易引起肝肾损伤、胃肠道反应,但骨质疏松、血脂升高以及疼痛感更为严重,两种药物对患者生活质量的影响不大,临床应根据患者的肝肾功能、骨质疏松以及血脂水平选择合适的药物治疗。Objective To study the effect of Aromatase inhibitor treatment on cancer pain and quality of life in patients with advanced breast cancer.Methods Thirty patients with advanced breast cancer who received different drug treatments in our hospital were randomly selected as the control group(30 cases,Exemestane)and the observation group(30 cases,letrozole),and the therapeutic effects of the two groups were compared.Results There was no statistically significant difference in ORR between the observation group(50.00%)and the control group(46.67%)(P>0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).There was no significant difference in joint pain between the two groups(P>0.05).There was no significant difference in E2 levels between the two groups after 4 weeks of treatment(P>0.05).The E2 in the observation group after 8 weeks of treatment significantly higher than the control group(P<0.05).The VAS score of the observation group was significantly lower than that of the control group(P<0.05).The SF-36 score of the observation group patients was significantly higher than that of the control group(P<0.05).Conclusion The therapeutic effects of the letrozole and exemestane are similar.Letrozole is not easy to cause liver and kidney damage,gastrointestinal reactions,but osteoporosis,increased blood lipid and pain are more serious.There is no significant difference in the impact of the two drugs on the quality of life of patients.Appropriate drug treatment should be selected according to the liver and kidney functions,osteoporosis and blood lipid levels of patients.

关 键 词：晚期乳腺癌 芳香化酶抑制剂 依西美坦 来曲唑 生活质量 癌性疼痛 

分 类 号：R737.9[医药卫生—肿瘤]